References
- Döhner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program 2011:36–42.
- Swerdlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
- Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29:487–494.
- Patel JP, Gönen M, Figueroa ME, . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079–1089.
- Chandrasekharappa SC, Gross LA, King SE, . The human NME2 gene lies within 18kb of NMEI in chromosome 17. Genes Chromosomes Cancer 1993;6:245–248.
- Backer JM, Mendola CE, Kovesdi I, . Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-I and NM23-2. Oncogene 1993;8:497–502.
- Postel EH, Zou X, Notterman DA, . Double knockout Nme1/Nme2 mouse model suggests a critical role for NDP kinases in erythroid development. Mol Cell Biochem 2009;329:45–50.
- MacDonald NJ, Rosa ADL, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 1995; 31A:1096–1100.
- Yokoyama A, Okabe-Kado J, Sakashita A, . Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia. Blood 1996;88:3555–3561.
- Döhner H, Estey EH, Amadori S, . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
- Bach E, Krahl R, Lange T, . Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia. Leuk Lymphoma 2012;53:1561–1568.
- Postel EH, Berberich SJ, Flint SJ, . Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. Science 1993;261:478–480.
- Berberich SJ, Postel EH. PuF/NM23-H2/NDPK-B transactivates a human c-myc promoter-CAT gene via a functional nuclease hypersensitive element. Oncogene 1995;10:2343–2347.
- Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992;70:901–910.
- Albajar M, Gómez-Casares MT, Llorca J, . MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res 2011;9:564–576.
- Tschiedel S, Bach E, Jilo A, . Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia. Leuk Lymphoma 2012;53: 1569–1576.